Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease (PL-10, PLD-116, PL 14736, Pliva) Current Pharmaceutical Design Comprehensive review of BPC 157 clinical development for inflammatory bowel disease including ulcerative colitis trials, demonstrating mucosal healing and anti-inflammatory effects across multiple organ systems
Int J Neuropsychopharmacol 14:106974
Full effects may take 4 to 8 weeks
Cagrilintides promise is as a stack partner to deepen satiety without relying on incretin pathways alone
Ipamorelin is a go-to option for people who want gentle, long-term support for energy, performance, and recovery
Follow-up check-ins, lab work where applicable, and ongoing provider involvement